IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
ยท To evaluate the disease free survival rate at 2 years of patients with advanced head and
neck carcinoma treated with ZD1839 250 mg administered once daily in combination with
cisplatin and a standard course of radiotherapy.